Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer

Inclusion Criteria: * Metastatic hormone refractory prostate cancer. * Eastern Cooperative Oncology Group (ECOG) Performance status of 0-1. * testosterone \<50ng/dL. Patients must continue primary androgen deprivation with an LHRH analogue if they have not undergone orchiectomy. * Progressive disease after androgen deprivation. Exclusion Criteria: * Patients whose clinical condition would make chemotherapy clearly indicated. * Patients who have received systemic chemotherapy for the treatment of metastatic disease. * Peripheral neuropathy \> Grade 1 * Prior anti-angiogenic therapy, including thalidomide. * Patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure or radiation within 4 weeks prior to study entry. * Patients who have received radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment. * Patients with known brain metastases or history of brain metastases. * History of stroke within 6 months of treatment or other significant neurological limitations. * Patients who have received more than 2 prior investigational treatments. * Uncontrolled intercurrent illness * Patients with a history of a myocardial infarction within the prior 6 months or, hospitalizations for decompensated congestive heart failure within the prior 6 months, or history of significant / symptomatic cardiac arrhythmias